Literature DB >> 3023540

Treatment of junin virus-infected guinea pigs with immune serum: development of late neurological disease.

R H Kenyon, D E Green, G A Eddy, C J Peters.   

Abstract

Guinea pigs infected with Argentine hemorrhagic fever virus (Junin) were treated with pooled, homologous convalescent sera. Use of 15,000 or 5,000 therapeutic units of immune sera prevented all signs of illness when administered within 24 hr of infection. We could also prevent illness and death in infected guinea pigs as late as 6 days after infection if we used more antisera (30,000 therapeutic units/kg). In some treatment groups, surviving animals developed a late neurological syndrome with prominent rear-limb paralysis. Treated animals typically expressed higher viral titers in the brain than in any other organ. There appeared to be no acute exacerbation of disease by antibody administration. Our data suggest that, after replicating peripherally, Junin virus infects the brain where circulating immunoglobulins may not eliminate viable virus. Subsequent replication of virus in the brain may generate a neurological phase of the illness. Histological examination of brains from guinea pigs in treatment groups favoring the neurological phase of illness showed encephalitis, meningitis, and swollen astrocytes, suggestive of neuronal degeneration. There is likely a delicate balance among presence of virus in the brain, the amount of antibody transported into the central nervous system, and the occurrence of this late neurological aspect of experimental Argentine hemorrhagic fever. Further study of this model may elucidate factors relevant in understanding the continuing problem of the late neurological syndrome seen in some human cases of Argentine hemorrhagic fever treated with immune plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023540     DOI: 10.1002/jmv.1890200303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  The glycoprotein precursor gene of Junin virus determines the virulence of the Romero strain and the attenuation of the Candid #1 strain in a representative animal model of Argentine hemorrhagic fever.

Authors:  Alexey V Seregin; Nadezhda E Yun; Milagros Miller; Judith Aronson; Jennifer K Smith; Aida G Walker; Jeanon N Smith; Cheng Huang; John T Manning; Juan C de la Torre; Slobodan Paessler
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

Review 2.  Epidemiology and pathogenesis of Bolivian hemorrhagic fever.

Authors:  Michael Patterson; Ashley Grant; Slobodan Paessler
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

3.  Guinea Pig Transferrin Receptor 1 Mediates Cellular Entry of Junín Virus and Other Pathogenic New World Arenaviruses.

Authors:  Brady T Hickerson; Jonna B Westover; Zhongde Wang; Young-Min Lee; Brian B Gowen
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

4.  Rescue of a recombinant Machupo virus from cloned cDNAs and in vivo characterization in interferon (αβ/γ) receptor double knockout mice.

Authors:  Michael Patterson; Alexey Seregin; Cheng Huang; Olga Kolokoltsova; Jennifer Smith; Milagros Miller; Jeanon Smith; Nadezhda Yun; Allison Poussard; Ashley Grant; Bersabeh Tigabu; Aida Walker; Slobodan Paessler
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

5.  Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs.

Authors:  Nadezhda E Yun; Nathaniel S Linde; Natallia Dziuba; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Judy F Aronson; Olga V Chumakova; Heather M Lander; Clarence J Peters; Slobodan Paessler
Journal:  Am J Trop Med Hyg       Date:  2008-08       Impact factor: 2.345

6.  Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Authors:  Joseph W Golden; Piet Maes; Steven A Kwilas; John Ballantyne; Jay W Hooper
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

7.  Monoclonal antibody therapy for Junin virus infection.

Authors:  Larry Zeitlin; Joan B Geisbert; Daniel J Deer; Karla A Fenton; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Andrew Hiatt; Michael H Pauly; Jesus Velasco; Kevin J Whaley; Friedrich Altmann; Clemens Gruber; Herta Steinkellner; Anna N Honko; Ana I Kuehne; M Javad Aman; Sara Sahandi; Sven Enterlein; Xiaoguo Zhan; Delia Enria; Thomas W Geisbert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

8.  Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine.

Authors:  Johannes Simon Gach; Heribert Quendler; Boris Ferko; Hermann Katinger; Renate Kunert
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

Review 9.  Animal models, prophylaxis, and therapeutics for arenavirus infections.

Authors:  Eric Vela
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

10.  Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.

Authors:  Brian B Gowen; Donald F Smee; Min-Hui Wong; Jeffery O Hall; Kie-Hoon Jung; Kevin W Bailey; John R Stevens; Yousuke Furuta; John D Morrey
Journal:  PLoS One       Date:  2008-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.